KR102439911B1 - 제약학적 복합제제 - Google Patents

제약학적 복합제제 Download PDF

Info

Publication number
KR102439911B1
KR102439911B1 KR1020187037798A KR20187037798A KR102439911B1 KR 102439911 B1 KR102439911 B1 KR 102439911B1 KR 1020187037798 A KR1020187037798 A KR 1020187037798A KR 20187037798 A KR20187037798 A KR 20187037798A KR 102439911 B1 KR102439911 B1 KR 102439911B1
Authority
KR
South Korea
Prior art keywords
delete delete
compound
cancer
braf
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187037798A
Other languages
English (en)
Korean (ko)
Other versions
KR20190119507A (ko
Inventor
조르다노 카포니그로
주 알렉산더 카오
Original Assignee
어레이 바이오파마 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60477982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102439911(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 어레이 바이오파마 인크. filed Critical 어레이 바이오파마 인크.
Publication of KR20190119507A publication Critical patent/KR20190119507A/ko
Application granted granted Critical
Publication of KR102439911B1 publication Critical patent/KR102439911B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187037798A 2016-06-03 2017-06-02 제약학적 복합제제 Active KR102439911B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345389P 2016-06-03 2016-06-03
US62/345,389 2016-06-03
PCT/US2017/035653 WO2017210538A1 (en) 2016-06-03 2017-06-02 Pharmaceutical combinations

Publications (2)

Publication Number Publication Date
KR20190119507A KR20190119507A (ko) 2019-10-22
KR102439911B1 true KR102439911B1 (ko) 2022-09-05

Family

ID=60477982

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187037798A Active KR102439911B1 (ko) 2016-06-03 2017-06-02 제약학적 복합제제

Country Status (26)

Country Link
US (3) US10485788B2 (enExample)
EP (1) EP3463345B1 (enExample)
JP (2) JP6805336B2 (enExample)
KR (1) KR102439911B1 (enExample)
CN (1) CN109890386B (enExample)
AU (1) AU2017275650B2 (enExample)
BR (1) BR112018074941A2 (enExample)
CA (1) CA3026361A1 (enExample)
CL (1) CL2018003421A1 (enExample)
CO (1) CO2019000010A2 (enExample)
CR (1) CR20190002A (enExample)
DK (1) DK3463345T3 (enExample)
FI (1) FI3463345T3 (enExample)
HU (1) HUE060653T2 (enExample)
IL (1) IL263431A (enExample)
MA (1) MA45187A (enExample)
MX (1) MX387795B (enExample)
PH (1) PH12018502549A1 (enExample)
PL (1) PL3463345T3 (enExample)
PT (1) PT3463345T (enExample)
RU (1) RU2759669C2 (enExample)
SG (1) SG11201810793XA (enExample)
SI (1) SI3463345T1 (enExample)
UA (1) UA125436C2 (enExample)
WO (1) WO2017210538A1 (enExample)
ZA (1) ZA201900019B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018074941A2 (pt) 2016-06-03 2019-03-12 Caponigro Giordano combinações farmacêuticas
KR102341660B1 (ko) * 2016-09-19 2021-12-23 노파르티스 아게 Raf 억제제 및 erk 억제제를 포함하는 치료적 조합
CN110494166B (zh) 2017-05-02 2022-11-08 诺华股份有限公司 组合疗法
BR112021022335A2 (pt) 2019-05-13 2021-12-28 Novartis Ag Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer
CN114746950A (zh) * 2019-10-11 2022-07-12 豪夫迈·罗氏有限公司 药物剂量确定设备和方法
US20230060581A1 (en) * 2020-02-10 2023-03-02 Cedars-Sinai Medical Center Method of treating pancreatic cancer
JP7288220B2 (ja) 2021-03-29 2023-06-07 ダイキン工業株式会社 モータ、送風装置、および冷凍装置
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
CN120359214A (zh) * 2022-12-15 2025-07-22 豪夫迈·罗氏有限公司 用于癌症治疗的组合疗法
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015008729A1 (ja) 2013-07-18 2015-01-22 株式会社ダイセル 酸化物の製造方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
TWI338685B (en) 2002-03-13 2011-03-11 Array Biopharma Inc N3 alkylated benzimid azole derivatives as mek inhibitors
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
HRP20120577T1 (hr) 2008-07-24 2012-08-31 Nerviano Medical Sciences S.R.L. 3,4-diarilpirazoli kao inhibitori proteinskih kinaza
JP5527878B2 (ja) * 2009-07-30 2014-06-25 トムソン ライセンシング 表示装置及び音声出力装置
AR077975A1 (es) * 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
EP2718485A4 (en) * 2011-06-07 2015-05-06 Caris Mpi Inc MOLECULAR PROFILING OF CANCER
BR112014011223A8 (pt) * 2011-11-11 2023-01-31 Novartis Ag Método de tratar uma doença proliferativa
MX353446B (es) 2011-11-23 2018-01-12 Novartis Ag Formulaciones farmaceuticas.
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
SG11201500321YA (en) 2012-08-07 2015-04-29 Novartis Ag Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
CN109336824B (zh) 2012-10-19 2022-11-11 诺华股份有限公司 Mek抑制剂的制备和包含mek抑制剂的制剂
MX2015005307A (es) * 2012-10-25 2015-07-17 Glaxosmithkline Llc Combinacion.
EP2976106B1 (en) 2013-03-21 2021-04-14 Array BioPharma Inc. Combination therapy comprising a b-raf inhibitor and a second inhibitor
US20150087279A1 (en) * 2013-09-20 2015-03-26 Better Mousetrap, LLC Mobile accident processing system and method
KR20160088884A (ko) * 2013-12-12 2016-07-26 노파르티스 아게 암의 치료를 위한 트라메티닙, 파니투무맙 및 다브라페닙의 조합물
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
WO2016155670A1 (zh) * 2015-04-01 2016-10-06 苏州晶云药物科技有限公司 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
US20170027951A1 (en) 2015-07-27 2017-02-02 Southern Research Institute Methods and compositions to treat cancers involving egfr
BR112018074941A2 (pt) 2016-06-03 2019-03-12 Caponigro Giordano combinações farmacêuticas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015008729A1 (ja) 2013-07-18 2015-01-22 株式会社ダイセル 酸化物の製造方法

Also Published As

Publication number Publication date
MX387795B (es) 2025-03-19
SG11201810793XA (en) 2018-12-28
PT3463345T (pt) 2023-01-06
EP3463345A4 (en) 2020-02-26
PL3463345T3 (pl) 2023-02-06
US10485788B2 (en) 2019-11-26
HUE060653T2 (hu) 2023-04-28
MA45187A (fr) 2019-04-10
US11376239B2 (en) 2022-07-05
BR112018074941A2 (pt) 2019-03-12
JP2021054832A (ja) 2021-04-08
CN109890386A (zh) 2019-06-14
PH12018502549A1 (en) 2019-04-08
CN109890386B (zh) 2022-05-24
US20230044943A1 (en) 2023-02-09
DK3463345T3 (da) 2023-01-09
CR20190002A (es) 2019-06-10
ZA201900019B (en) 2023-04-26
RU2759669C2 (ru) 2021-11-16
UA125436C2 (uk) 2022-03-09
WO2017210538A1 (en) 2017-12-07
FI3463345T3 (fi) 2023-01-31
AU2017275650A1 (en) 2019-01-17
JP2019525948A (ja) 2019-09-12
US20190105303A1 (en) 2019-04-11
IL263431A (en) 2019-01-31
SI3463345T1 (sl) 2023-02-28
RU2018146812A (ru) 2020-07-09
KR20190119507A (ko) 2019-10-22
MX2018014973A (es) 2019-12-18
US20200230108A1 (en) 2020-07-23
EP3463345B1 (en) 2022-11-02
RU2018146812A3 (enExample) 2020-10-09
EP3463345A1 (en) 2019-04-10
JP6805336B2 (ja) 2020-12-23
AU2017275650B2 (en) 2023-06-01
CO2019000010A2 (es) 2019-05-21
CA3026361A1 (en) 2017-12-07
CL2018003421A1 (es) 2019-07-19

Similar Documents

Publication Publication Date Title
KR102439911B1 (ko) 제약학적 복합제제
US20200281923A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
US20230118053A1 (en) Combination of anti-her2 antibody and cdk inhibitior for tumor treatment
CN115768416A (zh) 图卡替尼联合曲妥珠单抗和基于奥沙利铂的化学疗法治疗her2阳性癌症的方法
JP2022553041A (ja) Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法
US20240165112A1 (en) Therapy for the treatment of cancer
TWI814504B (zh) 治療癌症之方法
CN119997942A (zh) 用于治疗癌症的化合物
TW202302084A (zh) 以安森司坦和帕博西尼治療乳癌
US20250268900A1 (en) Combination therapy using a substituted pyrimidin-4(3h)-one and nivolumab as well as its use in the treatment of cancer
JP2015515476A (ja) Ｐｉ３ｋ阻害剤及びｍｅｋ阻害剤を使用する癌の治療方法
JP2015503568A (ja) トラスツズマブに不応性の乳癌の治療方法
WO2024263966A2 (en) Compositions comprising antineoplastons and methods of treating pancreatic cancer
WO2024263960A2 (en) Compositions comprising antineoplastons and methods of treating lung cancer
WO2024263801A2 (en) Compositions comprising antineoplastons and methods of treating ovarian cancer
WO2024263643A1 (en) Compositions comprising antineoplastons and methods of treating breast cancer
WO2024263813A2 (en) Compositions comprising antineoplastons and methods of treating colorectal cancer
WO2024263963A2 (en) Compositions comprising antineoplastons and methods of treating head and neck cancer
WO2024155790A2 (en) Novel approach for treatment of cancer using immunomodulation
WO2024263798A1 (en) Compositions comprising antineoplastons and methods of treating prostate cancer
JP2022547311A (ja) 骨髄線維症の治療のためのｍｄｍ２阻害剤の使用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200515

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220103

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220531

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220831

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220831

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250625

Start annual number: 4

End annual number: 4